MXPA01009727A - Composiciones y metodos para afectar los niveles de colesterol asociado a lipoproteina de alta densidad (hdl) y a apolipoproteina a1, colesterol asociado a lipoproteina de muy baja densidad (vldl) y colesterol asociado a lipoproteina de baja densidad - Google Patents

Info

Publication number

MXPA01009727A

MXPA01009727A MXPA01009727A MXPA01009727A MXPA01009727A MX PA01009727 A MXPA01009727 A MX PA01009727A MX PA01009727 A MXPA01009727 A MX PA01009727A MX PA01009727 A MXPA01009727 A MX PA01009727A MX PA01009727 A MXPA01009727 A MX PA01009727A

Authority

MX

Mexico

Prior art keywords

lipg

cholesterol

gly

leu

polypeptide

Prior art date

1999-03-26

Links

• Espacenet
• Global Dossier
• Discuss

• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title claims abstract description 403
• 235000012000 cholesterol Nutrition 0.000 title claims abstract description 140
• 238000000034 method Methods 0.000 title claims abstract description 137
• 239000000203 mixture Substances 0.000 title claims abstract description 128
• 102000005666 Apolipoprotein A-I Human genes 0.000 title claims abstract description 6
• 108010059886 Apolipoprotein A-I Proteins 0.000 title claims abstract description 6
• 102000015779 HDL Lipoproteins Human genes 0.000 title claims description 110
• 108010010234 HDL Lipoproteins Proteins 0.000 title claims description 110
• 108010007622 LDL Lipoproteins Proteins 0.000 title claims description 89
• 102000007330 LDL Lipoproteins Human genes 0.000 title claims description 89
• 108010062497 VLDL Lipoproteins Proteins 0.000 title claims description 71
• 108010022197 lipoprotein cholesterol Proteins 0.000 title claims description 5
• 102100031375 Endothelial lipase Human genes 0.000 claims abstract description 414
• 101000941275 Homo sapiens Endothelial lipase Proteins 0.000 claims abstract description 367
• 230000014509 gene expression Effects 0.000 claims abstract description 107
• 230000000694 effects Effects 0.000 claims abstract description 84
• 230000002255 enzymatic effect Effects 0.000 claims abstract description 55
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 236
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 213
• 229920001184 polypeptide Polymers 0.000 claims description 206
• 239000013598 vector Substances 0.000 claims description 126
• 150000007523 nucleic acids Chemical class 0.000 claims description 96
• 102000039446 nucleic acids Human genes 0.000 claims description 90
• 108020004707 nucleic acids Proteins 0.000 claims description 90
• 230000000692 anti-sense effect Effects 0.000 claims description 54
• 108091092562 ribozyme Proteins 0.000 claims description 52
• 108090000994 Catalytic RNA Proteins 0.000 claims description 51
• 102000053642 Catalytic RNA Human genes 0.000 claims description 51
• 239000013604 expression vector Substances 0.000 claims description 51
• 108020004414 DNA Proteins 0.000 claims description 50
• 108020004999 messenger RNA Proteins 0.000 claims description 50
• 150000001875 compounds Chemical class 0.000 claims description 47
• 230000001965 increasing effect Effects 0.000 claims description 44
• 230000002401 inhibitory effect Effects 0.000 claims description 41
• 108010071619 Apolipoproteins Proteins 0.000 claims description 38
• 102000007592 Apolipoproteins Human genes 0.000 claims description 38
• 230000003247 decreasing effect Effects 0.000 claims description 35
• 239000003623 enhancer Substances 0.000 claims description 34
• 101150107380 LIPG gene Proteins 0.000 claims description 32
• 238000012360 testing method Methods 0.000 claims description 31
• 230000027455 binding Effects 0.000 claims description 27
• 239000013603 viral vector Substances 0.000 claims description 24
• 108091028043 Nucleic acid sequence Proteins 0.000 claims description 23
• 108091034117 Oligonucleotide Proteins 0.000 claims description 23
• 239000003112 inhibitor Substances 0.000 claims description 23
• 239000003814 drug Substances 0.000 claims description 22
• 239000002502 liposome Substances 0.000 claims description 22
• 230000001177 retroviral effect Effects 0.000 claims description 22
• 230000007423 decrease Effects 0.000 claims description 21
• 238000006911 enzymatic reaction Methods 0.000 claims description 19
• 230000003834 intracellular effect Effects 0.000 claims description 16
• 230000003472 neutralizing effect Effects 0.000 claims description 15
• 108091061960 Naked DNA Proteins 0.000 claims description 14
• 108091008324 binding proteins Proteins 0.000 claims description 14
• 241000175212 Herpesvirales Species 0.000 claims description 11
• 210000004369 blood Anatomy 0.000 claims description 9
• 239000008280 blood Substances 0.000 claims description 9
• 239000003937 drug carrier Substances 0.000 claims description 9
• 239000000126 substance Substances 0.000 claims description 9
• 125000002091 cationic group Chemical group 0.000 claims description 8
• 229940079593 drug Drugs 0.000 claims description 4
• 238000003018 immunoassay Methods 0.000 claims description 2
• 102000023732 binding proteins Human genes 0.000 claims 4
• 102000053602 DNA Human genes 0.000 claims 1
• 101100289061 Drosophila melanogaster lili gene Proteins 0.000 claims 1
• 108090001102 Hammerhead ribozyme Proteins 0.000 claims 1
• 108090000623 proteins and genes Proteins 0.000 abstract description 126
• 108090001060 Lipase Proteins 0.000 abstract description 51
• 102000004882 Lipase Human genes 0.000 abstract description 47
• 102000004190 Enzymes Human genes 0.000 abstract description 22
• 108090000790 Enzymes Proteins 0.000 abstract description 22
• 238000008214 LDL Cholesterol Methods 0.000 abstract 1
• 108010069201 VLDL Cholesterol Proteins 0.000 abstract 1
• 210000004027 cell Anatomy 0.000 description 159
• 102000004169 proteins and genes Human genes 0.000 description 81
• 235000018102 proteins Nutrition 0.000 description 80
• 239000002299 complementary DNA Substances 0.000 description 66
• 239000000523 sample Substances 0.000 description 56
• 101710087274 Endothelial lipase Proteins 0.000 description 55
• 150000002632 lipids Chemical class 0.000 description 55
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 54
• 210000001519 tissue Anatomy 0.000 description 54
• 238000006243 chemical reaction Methods 0.000 description 48
• 239000000047 product Substances 0.000 description 48
• 239000000758 substrate Substances 0.000 description 46
• 241000701161 unidentified adenovirus Species 0.000 description 40
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 36
• 239000012634 fragment Substances 0.000 description 34
• 241000699670 Mus sp. Species 0.000 description 33
• 102000004895 Lipoproteins Human genes 0.000 description 32
• 108090001030 Lipoproteins Proteins 0.000 description 32
• 239000012528 membrane Substances 0.000 description 30
• 108010064785 Phospholipases Proteins 0.000 description 29
• 102000015439 Phospholipases Human genes 0.000 description 29
• 102000019267 Hepatic lipases Human genes 0.000 description 27
• 108050006747 Hepatic lipases Proteins 0.000 description 27
• ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 26
• 241001465754 Metazoa Species 0.000 description 26
• 238000003556 assay Methods 0.000 description 26
• 239000003636 conditioned culture medium Substances 0.000 description 26
• 238000002347 injection Methods 0.000 description 25
• 239000007924 injection Substances 0.000 description 25
• PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 25
• PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 24
• 241000700605 Viruses Species 0.000 description 24
• 210000004185 liver Anatomy 0.000 description 24
• 238000003199 nucleic acid amplification method Methods 0.000 description 24
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
• 239000004367 Lipase Substances 0.000 description 23
• 235000019421 lipase Nutrition 0.000 description 23
• 239000013612 plasmid Substances 0.000 description 23
• 201000001320 Atherosclerosis Diseases 0.000 description 22
• 108010013563 Lipoprotein Lipase Proteins 0.000 description 22
• 102000043296 Lipoprotein lipases Human genes 0.000 description 22
• 235000001014 amino acid Nutrition 0.000 description 22
• 229920000669 heparin Polymers 0.000 description 22
• 229960002897 heparin Drugs 0.000 description 22
• 229940088598 enzyme Drugs 0.000 description 21
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 20
• 229940024606 amino acid Drugs 0.000 description 20
• 150000001413 amino acids Chemical class 0.000 description 20
• 239000000872 buffer Substances 0.000 description 20
• 239000002609 medium Substances 0.000 description 20
• 150000003904 phospholipids Chemical class 0.000 description 20
• 239000000243 solution Substances 0.000 description 20
• 238000011282 treatment Methods 0.000 description 20
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 19
• YOKVEHGYYQEQOP-QWRGUYRKSA-N Leu-Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O YOKVEHGYYQEQOP-QWRGUYRKSA-N 0.000 description 19
• 230000003321 amplification Effects 0.000 description 19
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 18
• 230000002950 deficient Effects 0.000 description 18
• 230000001105 regulatory effect Effects 0.000 description 18
• 241000283973 Oryctolagus cuniculus Species 0.000 description 17
• 238000004458 analytical method Methods 0.000 description 17
• 230000003197 catalytic effect Effects 0.000 description 17
• 238000001727 in vivo Methods 0.000 description 17
• 239000002773 nucleotide Substances 0.000 description 17
• 125000003729 nucleotide group Chemical group 0.000 description 17
• WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Inorganic materials [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 17
• 102000019280 Pancreatic lipases Human genes 0.000 description 16
• 210000002889 endothelial cell Anatomy 0.000 description 16
• 229940116369 pancreatic lipase Drugs 0.000 description 16
• WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 16
• 241000894007 species Species 0.000 description 16
• UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 16
• -1 Lipids Lipids Chemical class 0.000 description 15
• 108050006759 Pancreatic lipases Proteins 0.000 description 15
• 229940040461 lipase Drugs 0.000 description 15
• 239000000074 antisense oligonucleotide Substances 0.000 description 14
• 238000012230 antisense oligonucleotides Methods 0.000 description 14
• 239000000499 gel Substances 0.000 description 14
• 235000019626 lipase activity Nutrition 0.000 description 14
• 150000003626 triacylglycerols Chemical class 0.000 description 14
• 102000014914 Carrier Proteins Human genes 0.000 description 13
• 230000006870 function Effects 0.000 description 13
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 12
• 239000003153 chemical reaction reagent Substances 0.000 description 12
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
• 239000000194 fatty acid Substances 0.000 description 12
• 238000001890 transfection Methods 0.000 description 12
• 230000003612 virological effect Effects 0.000 description 12
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 11
• 229920002684 Sepharose Polymers 0.000 description 11
• 230000003143 atherosclerotic effect Effects 0.000 description 11
• 230000000875 corresponding effect Effects 0.000 description 11
• 235000014113 dietary fatty acids Nutrition 0.000 description 11
• 229930195729 fatty acid Natural products 0.000 description 11
• 150000004665 fatty acids Chemical class 0.000 description 11
• 239000003999 initiator Substances 0.000 description 11
• 210000002826 placenta Anatomy 0.000 description 11
• 230000010076 replication Effects 0.000 description 11
• 239000011780 sodium chloride Substances 0.000 description 11
• 238000013518 transcription Methods 0.000 description 11
• 230000035897 transcription Effects 0.000 description 11
• 241001430294 unidentified retrovirus Species 0.000 description 11
• 238000001262 western blot Methods 0.000 description 11
• 108700008625 Reporter Genes Proteins 0.000 description 10
• 238000010367 cloning Methods 0.000 description 10
• 201000010099 disease Diseases 0.000 description 10
• 238000010253 intravenous injection Methods 0.000 description 10
• 239000002245 particle Substances 0.000 description 10
• 210000002966 serum Anatomy 0.000 description 10
• 238000012546 transfer Methods 0.000 description 10
• 230000009261 transgenic effect Effects 0.000 description 10
• 239000003981 vehicle Substances 0.000 description 10
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
• 125000003275 alpha amino acid group Chemical group 0.000 description 9
• 210000004556 brain Anatomy 0.000 description 9
• FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 9
• 238000009396 hybridization Methods 0.000 description 9
• 238000000338 in vitro Methods 0.000 description 9
• 238000001802 infusion Methods 0.000 description 9
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
• 239000001103 potassium chloride Substances 0.000 description 9
• 238000002360 preparation method Methods 0.000 description 9
• 238000000746 purification Methods 0.000 description 9
• 229940117972 triolein Drugs 0.000 description 9
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 8
• 241000282412 Homo Species 0.000 description 8
• 241000699660 Mus musculus Species 0.000 description 8
• 102000039013 Triacylglycerol lipase family Human genes 0.000 description 8
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 8
• 238000007792 addition Methods 0.000 description 8
• 230000004071 biological effect Effects 0.000 description 8
• 210000000349 chromosome Anatomy 0.000 description 8
• 238000012217 deletion Methods 0.000 description 8
• 230000037430 deletion Effects 0.000 description 8
• 238000002474 experimental method Methods 0.000 description 8
• 239000012091 fetal bovine serum Substances 0.000 description 8
• 238000001415 gene therapy Methods 0.000 description 8
• 238000011534 incubation Methods 0.000 description 8
• 238000011830 transgenic mouse model Methods 0.000 description 8
• 238000005406 washing Methods 0.000 description 8
• 241000283690 Bos taurus Species 0.000 description 7
• 108010023302 HDL Cholesterol Proteins 0.000 description 7
• 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 7
• 108091063501 Triacylglycerol lipase family Proteins 0.000 description 7
• BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 description 7
• PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 7
• 230000015572 biosynthetic process Effects 0.000 description 7
• 208000029078 coronary artery disease Diseases 0.000 description 7
• 235000005911 diet Nutrition 0.000 description 7
• 210000003527 eukaryotic cell Anatomy 0.000 description 7
• 239000000284 extract Substances 0.000 description 7
• 235000021588 free fatty acids Nutrition 0.000 description 7
• 102000045333 human LIPG Human genes 0.000 description 7
• 208000001024 intrahepatic cholestasis Diseases 0.000 description 7
• 230000007872 intrahepatic cholestasis Effects 0.000 description 7
• 210000003734 kidney Anatomy 0.000 description 7
• 210000004072 lung Anatomy 0.000 description 7
• 230000001404 mediated effect Effects 0.000 description 7
• 239000013600 plasmid vector Substances 0.000 description 7
• 150000003384 small molecules Chemical class 0.000 description 7
• 238000013519 translation Methods 0.000 description 7
• PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 7
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
• 101000619884 Homo sapiens Lipoprotein lipase Proteins 0.000 description 6
• TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
• RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 6
• 108010076504 Protein Sorting Signals Proteins 0.000 description 6
• 239000007983 Tris buffer Substances 0.000 description 6
• YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 6
• 125000000539 amino acid group Chemical group 0.000 description 6
• 230000000890 antigenic effect Effects 0.000 description 6
• 230000000923 atherogenic effect Effects 0.000 description 6
• 230000008901 benefit Effects 0.000 description 6
• 229940098773 bovine serum albumin Drugs 0.000 description 6
• 239000012141 concentrate Substances 0.000 description 6
• 238000012790 confirmation Methods 0.000 description 6
• 239000000839 emulsion Substances 0.000 description 6
• 230000002068 genetic effect Effects 0.000 description 6
• 230000013595 glycosylation Effects 0.000 description 6
• 238000006206 glycosylation reaction Methods 0.000 description 6
• 102000045312 human LPL Human genes 0.000 description 6
• 230000004048 modification Effects 0.000 description 6
• 238000012986 modification Methods 0.000 description 6
• 229920000642 polymer Polymers 0.000 description 6
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
• 230000009467 reduction Effects 0.000 description 6
• 230000002829 reductive effect Effects 0.000 description 6
• 230000000699 topical effect Effects 0.000 description 6
• 230000032258 transport Effects 0.000 description 6
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
• ZHSGGJXRNHWHRS-VIDYELAYSA-N tunicamycin Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](O)[C@@H](CC(O)[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)O1)O)NC(=O)/C=C/CC(C)C)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O ZHSGGJXRNHWHRS-VIDYELAYSA-N 0.000 description 6
• MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 6
• 230000002792 vascular Effects 0.000 description 6
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 5
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 5
• 108020004705 Codon Proteins 0.000 description 5
• 241000702421 Dependoparvovirus Species 0.000 description 5
• 102100034343 Integrase Human genes 0.000 description 5
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
• 108010001831 LDL receptors Proteins 0.000 description 5
• 238000000636 Northern blotting Methods 0.000 description 5
• 238000012408 PCR amplification Methods 0.000 description 5
• 201000002150 Progressive familial intrahepatic cholestasis Diseases 0.000 description 5
• 239000002253 acid Substances 0.000 description 5
• 239000002671 adjuvant Substances 0.000 description 5
• 210000000709 aorta Anatomy 0.000 description 5
• 210000004204 blood vessel Anatomy 0.000 description 5
• 239000001110 calcium chloride Substances 0.000 description 5
• 229910001628 calcium chloride Inorganic materials 0.000 description 5
• 230000000295 complement effect Effects 0.000 description 5
• 238000010276 construction Methods 0.000 description 5
• 238000011161 development Methods 0.000 description 5
• 230000018109 developmental process Effects 0.000 description 5
• 230000037213 diet Effects 0.000 description 5
• 230000029087 digestion Effects 0.000 description 5
• 238000001962 electrophoresis Methods 0.000 description 5
• 238000004945 emulsification Methods 0.000 description 5
• 230000002708 enhancing effect Effects 0.000 description 5
• 239000000787 lecithin Substances 0.000 description 5
• 229940067606 lecithin Drugs 0.000 description 5
• 235000010445 lecithin Nutrition 0.000 description 5
• 230000003902 lesion Effects 0.000 description 5
• 210000004962 mammalian cell Anatomy 0.000 description 5
• 238000004519 manufacturing process Methods 0.000 description 5
• 229960000502 poloxamer Drugs 0.000 description 5
• 229920001983 poloxamer Polymers 0.000 description 5
• 239000002243 precursor Substances 0.000 description 5
• 230000002787 reinforcement Effects 0.000 description 5
• 210000002027 skeletal muscle Anatomy 0.000 description 5
• 238000003786 synthesis reaction Methods 0.000 description 5
• 238000002560 therapeutic procedure Methods 0.000 description 5
• RLMISHABBKUNFO-WHFBIAKZSA-N Ala-Ala-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O RLMISHABBKUNFO-WHFBIAKZSA-N 0.000 description 4
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 4
• 241000699800 Cricetinae Species 0.000 description 4
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
• 101001066129 Homo sapiens Glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 4
• 101001134456 Homo sapiens Pancreatic triacylglycerol lipase Proteins 0.000 description 4
• 108010046315 IDL Lipoproteins Proteins 0.000 description 4
• 241000699666 Mus <mouse, genus> Species 0.000 description 4
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
• 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 4
• 241000700159 Rattus Species 0.000 description 4
• 108010083644 Ribonucleases Proteins 0.000 description 4
• 102000006382 Ribonucleases Human genes 0.000 description 4
• 241000251131 Sphyrna Species 0.000 description 4
• 239000011543 agarose gel Substances 0.000 description 4
• 201000001493 benign recurrent intrahepatic cholestasis Diseases 0.000 description 4
• 230000000903 blocking effect Effects 0.000 description 4
• 235000011148 calcium chloride Nutrition 0.000 description 4
• 230000015556 catabolic process Effects 0.000 description 4
• 230000001413 cellular effect Effects 0.000 description 4
• 238000005119 centrifugation Methods 0.000 description 4
• 210000004748 cultured cell Anatomy 0.000 description 4
• 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 4
• 238000009826 distribution Methods 0.000 description 4
• 238000005516 engineering process Methods 0.000 description 4
• 230000029142 excretion Effects 0.000 description 4
• 230000012010 growth Effects 0.000 description 4
• 102000047486 human GAPDH Human genes 0.000 description 4
• 239000000017 hydrogel Substances 0.000 description 4
• 230000001939 inductive effect Effects 0.000 description 4
• 230000005764 inhibitory process Effects 0.000 description 4
• 238000011081 inoculation Methods 0.000 description 4
• 238000007912 intraperitoneal administration Methods 0.000 description 4
• 238000001990 intravenous administration Methods 0.000 description 4
• PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 4
• 238000005259 measurement Methods 0.000 description 4
• 230000004060 metabolic process Effects 0.000 description 4
• 238000012544 monitoring process Methods 0.000 description 4
• 239000013642 negative control Substances 0.000 description 4
• 108010071584 oxidized low density lipoprotein Proteins 0.000 description 4
• 210000000496 pancreas Anatomy 0.000 description 4
• 238000012545 processing Methods 0.000 description 4
• 230000000644 propagated effect Effects 0.000 description 4
• 102000005962 receptors Human genes 0.000 description 4
• 108020003175 receptors Proteins 0.000 description 4
• 238000007920 subcutaneous administration Methods 0.000 description 4
• 239000000725 suspension Substances 0.000 description 4
• 230000001225 therapeutic effect Effects 0.000 description 4
• 230000002103 transcriptional effect Effects 0.000 description 4
• VLEIUWBSEKKKFX-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O VLEIUWBSEKKKFX-UHFFFAOYSA-N 0.000 description 3
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
• 102000007469 Actins Human genes 0.000 description 3
• 108010085238 Actins Proteins 0.000 description 3
• 229920001817 Agar Polymers 0.000 description 3
• 241000972773 Aulopiformes Species 0.000 description 3
• 108010078791 Carrier Proteins Proteins 0.000 description 3
• 108010004103 Chylomicrons Proteins 0.000 description 3
• 101710177611 DNA polymerase II large subunit Proteins 0.000 description 3
• 101710184669 DNA polymerase II small subunit Proteins 0.000 description 3
• 241000588724 Escherichia coli Species 0.000 description 3
• 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 3
• 241000238631 Hexapoda Species 0.000 description 3
• 101000941289 Homo sapiens Hepatic triacylglycerol lipase Proteins 0.000 description 3
• 101001051093 Homo sapiens Low-density lipoprotein receptor Proteins 0.000 description 3
• 208000035150 Hypercholesterolemia Diseases 0.000 description 3
• 108060003951 Immunoglobulin Proteins 0.000 description 3
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
• 241001529936 Murinae Species 0.000 description 3
• 239000000020 Nitrocellulose Substances 0.000 description 3
• 101710163270 Nuclease Proteins 0.000 description 3
• 108010067787 Proteoglycans Proteins 0.000 description 3
• 102000016611 Proteoglycans Human genes 0.000 description 3
• 101100173636 Rattus norvegicus Fhl2 gene Proteins 0.000 description 3
• 108010071390 Serum Albumin Proteins 0.000 description 3
• 102000007562 Serum Albumin Human genes 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• 241000282887 Suidae Species 0.000 description 3
• 108020005202 Viral DNA Proteins 0.000 description 3
• 238000009825 accumulation Methods 0.000 description 3
• 239000008272 agar Substances 0.000 description 3
• 230000002788 anti-peptide Effects 0.000 description 3
• 238000001574 biopsy Methods 0.000 description 3
• 230000037396 body weight Effects 0.000 description 3
• 238000010804 cDNA synthesis Methods 0.000 description 3
• AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 3
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
• 238000004113 cell culture Methods 0.000 description 3
• 239000013592 cell lysate Substances 0.000 description 3
• 210000000170 cell membrane Anatomy 0.000 description 3
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
• 150000001840 cholesterol esters Chemical class 0.000 description 3
• 238000001816 cooling Methods 0.000 description 3
• 210000004351 coronary vessel Anatomy 0.000 description 3
• 230000008878 coupling Effects 0.000 description 3
• 238000010168 coupling process Methods 0.000 description 3
• 238000005859 coupling reaction Methods 0.000 description 3
• 235000018417 cysteine Nutrition 0.000 description 3
• 230000007547 defect Effects 0.000 description 3
• 229960000633 dextran sulfate Drugs 0.000 description 3
• 238000005538 encapsulation Methods 0.000 description 3
• 230000003511 endothelial effect Effects 0.000 description 3
• 108700004026 gag Genes Proteins 0.000 description 3
• 239000005556 hormone Substances 0.000 description 3
• 229940088597 hormone Drugs 0.000 description 3
• 102000057438 human LIPC Human genes 0.000 description 3
• 102000046759 human PNLIP Human genes 0.000 description 3
• 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 3
• 230000003053 immunization Effects 0.000 description 3
• 230000002163 immunogen Effects 0.000 description 3
• 102000018358 immunoglobulin Human genes 0.000 description 3
• 230000003993 interaction Effects 0.000 description 3
• 238000010255 intramuscular injection Methods 0.000 description 3
• 239000007927 intramuscular injection Substances 0.000 description 3
• 238000007913 intrathecal administration Methods 0.000 description 3
• 238000001638 lipofection Methods 0.000 description 3
• 210000002540 macrophage Anatomy 0.000 description 3
• 229910001629 magnesium chloride Inorganic materials 0.000 description 3
• 238000012423 maintenance Methods 0.000 description 3
• 239000003550 marker Substances 0.000 description 3
• 230000002503 metabolic effect Effects 0.000 description 3
• 239000004005 microsphere Substances 0.000 description 3
• 229920001220 nitrocellulos Polymers 0.000 description 3
• 229910052757 nitrogen Inorganic materials 0.000 description 3
• 231100000252 nontoxic Toxicity 0.000 description 3
• 230000003000 nontoxic effect Effects 0.000 description 3
• 238000004806 packaging method and process Methods 0.000 description 3
• 230000002093 peripheral effect Effects 0.000 description 3
• 239000008363 phosphate buffer Substances 0.000 description 3
• 239000000902 placebo Substances 0.000 description 3
• 229940068196 placebo Drugs 0.000 description 3
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
• 230000003389 potentiating effect Effects 0.000 description 3
• 230000008569 process Effects 0.000 description 3
• 238000007634 remodeling Methods 0.000 description 3
• 238000011160 research Methods 0.000 description 3
• 235000019515 salmon Nutrition 0.000 description 3
• 238000002805 secondary assay Methods 0.000 description 3
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
• 239000001488 sodium phosphate Substances 0.000 description 3
• 210000004989 spleen cell Anatomy 0.000 description 3
• 239000003381 stabilizer Substances 0.000 description 3
• 238000010561 standard procedure Methods 0.000 description 3
• 230000000638 stimulation Effects 0.000 description 3
• 238000003860 storage Methods 0.000 description 3
• 238000006467 substitution reaction Methods 0.000 description 3
• 230000008685 targeting Effects 0.000 description 3
• 210000001685 thyroid gland Anatomy 0.000 description 3
• DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 3
• 238000005199 ultracentrifugation Methods 0.000 description 3
• 241000701447 unidentified baculovirus Species 0.000 description 3
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
• PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
• WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
• RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 2
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
• AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 2
• LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
• HSHNITRMYYLLCV-UHFFFAOYSA-N 4-methylumbelliferone Chemical compound C1=C(O)C=CC2=C1OC(=O)C=C2C HSHNITRMYYLLCV-UHFFFAOYSA-N 0.000 description 2
• QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
• WRDABNWSWOHGMS-UHFFFAOYSA-N AEBSF hydrochloride Chemical compound Cl.NCCC1=CC=C(S(F)(=O)=O)C=C1 WRDABNWSWOHGMS-UHFFFAOYSA-N 0.000 description 2
• HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
• 108020005544 Antisense RNA Proteins 0.000 description 2
• 102000018616 Apolipoproteins B Human genes 0.000 description 2
• 108010027006 Apolipoproteins B Proteins 0.000 description 2
• 102000006410 Apoproteins Human genes 0.000 description 2
• 108010083590 Apoproteins Proteins 0.000 description 2
• 206010003210 Arteriosclerosis Diseases 0.000 description 2
• 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
• 241000894006 Bacteria Species 0.000 description 2
• 101000909256 Caldicellulosiruptor bescii (strain ATCC BAA-1888 / DSM 6725 / Z-1320) DNA polymerase I Proteins 0.000 description 2
• 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
• 108091026890 Coding region Proteins 0.000 description 2
• SRIRHERUAMYIOQ-CIUDSAMLSA-N Cys-Leu-Ser Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O SRIRHERUAMYIOQ-CIUDSAMLSA-N 0.000 description 2
• 241000701022 Cytomegalovirus Species 0.000 description 2
• 108010017826 DNA Polymerase I Proteins 0.000 description 2
• 102000004594 DNA Polymerase I Human genes 0.000 description 2
• 241000450599 DNA viruses Species 0.000 description 2
• 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
• 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
• 238000002965 ELISA Methods 0.000 description 2
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• 102000004366 Glucosidases Human genes 0.000 description 2
• 108010056771 Glucosidases Proteins 0.000 description 2
• 102000003886 Glycoproteins Human genes 0.000 description 2
• 108090000288 Glycoproteins Proteins 0.000 description 2
• 239000007995 HEPES buffer Substances 0.000 description 2
• 230000010556 Heparin Binding Activity Effects 0.000 description 2
• 241000724709 Hepatitis delta virus Species 0.000 description 2
• 101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 description 2
• 101001040800 Homo sapiens Integral membrane protein GPR180 Proteins 0.000 description 2
• 208000031226 Hyperlipidaemia Diseases 0.000 description 2
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
• 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 2
• 241000713666 Lentivirus Species 0.000 description 2
• PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 2
• 102000005348 Neuraminidase Human genes 0.000 description 2
• 108010006232 Neuraminidase Proteins 0.000 description 2
• 241000221960 Neurospora Species 0.000 description 2
• 239000005642 Oleic acid Substances 0.000 description 2
• ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
• 108700026244 Open Reading Frames Proteins 0.000 description 2
• KPKZJLCSROULON-QKGLWVMZSA-N Phalloidin Chemical compound N1C(=O)[C@@H]([C@@H](O)C)NC(=O)[C@H](C)NC(=O)[C@H](C[C@@](C)(O)CO)NC(=O)[C@H](C2)NC(=O)[C@H](C)NC(=O)[C@@H]3C[C@H](O)CN3C(=O)[C@@H]1CSC1=C2C2=CC=CC=C2N1 KPKZJLCSROULON-QKGLWVMZSA-N 0.000 description 2
• PEFJUUYFEGBXFA-BZSNNMDCSA-N Phe-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CC=CC=C1 PEFJUUYFEGBXFA-BZSNNMDCSA-N 0.000 description 2
• 206010035226 Plasma cell myeloma Diseases 0.000 description 2
• 229920001213 Polysorbate 20 Polymers 0.000 description 2
• 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
• 101000902592 Pyrococcus furiosus (strain ATCC 43587 / DSM 3638 / JCM 8422 / Vc1) DNA polymerase Proteins 0.000 description 2
• 108091034057 RNA (poly(A)) Proteins 0.000 description 2
• 102000014450 RNA Polymerase III Human genes 0.000 description 2
• 108010078067 RNA Polymerase III Proteins 0.000 description 2
• 108020004511 Recombinant DNA Proteins 0.000 description 2
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
• 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 2
• 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 2
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
• 108010006785 Taq Polymerase Proteins 0.000 description 2
• 239000004098 Tetracycline Substances 0.000 description 2
• 108700005077 Viral Genes Proteins 0.000 description 2
• YFUAMNHCERJFPS-UHFFFAOYSA-N [K+].OB(O)[O-].OC(O)=O Chemical compound [K+].OB(O)[O-].OC(O)=O YFUAMNHCERJFPS-UHFFFAOYSA-N 0.000 description 2
• 239000012190 activator Substances 0.000 description 2
• 210000000577 adipose tissue Anatomy 0.000 description 2
• 239000000443 aerosol Substances 0.000 description 2
• 238000000246 agarose gel electrophoresis Methods 0.000 description 2
• 230000002776 aggregation Effects 0.000 description 2
• 238000004220 aggregation Methods 0.000 description 2
• 238000010171 animal model Methods 0.000 description 2
• 239000008346 aqueous phase Substances 0.000 description 2
• YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
• 208000037741 atherosclerosis susceptibility Diseases 0.000 description 2
• 238000000376 autoradiography Methods 0.000 description 2
• 229920001222 biopolymer Polymers 0.000 description 2
• 238000009835 boiling Methods 0.000 description 2
• UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 2
• 239000001506 calcium phosphate Substances 0.000 description 2
• 229910000389 calcium phosphate Inorganic materials 0.000 description 2
• 235000011010 calcium phosphates Nutrition 0.000 description 2
• 150000001720 carbohydrates Chemical class 0.000 description 2
• 235000014633 carbohydrates Nutrition 0.000 description 2
• OKTJSMMVPCPJKN-YPZZEJLDSA-N carbon-10 atom Chemical compound [10C] OKTJSMMVPCPJKN-YPZZEJLDSA-N 0.000 description 2
• 230000000747 cardiac effect Effects 0.000 description 2
• 210000001715 carotid artery Anatomy 0.000 description 2
• 239000007795 chemical reaction product Substances 0.000 description 2
• 239000003795 chemical substances by application Substances 0.000 description 2
• KMRSOJFYKZALJY-UHFFFAOYSA-N chloroform;heptane;methanol Chemical compound OC.ClC(Cl)Cl.CCCCCCC KMRSOJFYKZALJY-UHFFFAOYSA-N 0.000 description 2
• 238000011210 chromatographic step Methods 0.000 description 2
• 238000004587 chromatography analysis Methods 0.000 description 2
• 230000002759 chromosomal effect Effects 0.000 description 2
• 239000003184 complementary RNA Substances 0.000 description 2
• 230000001143 conditioned effect Effects 0.000 description 2
• 230000021615 conjugation Effects 0.000 description 2
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
• 231100000433 cytotoxic Toxicity 0.000 description 2
• 230000001472 cytotoxic effect Effects 0.000 description 2
• SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
• SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 2
• 230000007812 deficiency Effects 0.000 description 2
• 238000006731 degradation reaction Methods 0.000 description 2
• 239000000412 dendrimer Substances 0.000 description 2
• 229920000736 dendritic polymer Polymers 0.000 description 2
• 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
• 238000011033 desalting Methods 0.000 description 2
• 238000003745 diagnosis Methods 0.000 description 2
• 230000000378 dietary effect Effects 0.000 description 2
• 230000004069 differentiation Effects 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• 229910000397 disodium phosphate Inorganic materials 0.000 description 2
• 231100000673 dose–response relationship Toxicity 0.000 description 2
• 230000002222 downregulating effect Effects 0.000 description 2
• 230000002526 effect on cardiovascular system Effects 0.000 description 2
• 238000004520 electroporation Methods 0.000 description 2
• 210000003038 endothelium Anatomy 0.000 description 2
• 108700004025 env Genes Proteins 0.000 description 2
• 238000007824 enzymatic assay Methods 0.000 description 2
• 238000011156 evaluation Methods 0.000 description 2
• 238000000605 extraction Methods 0.000 description 2
• 239000003925 fat Substances 0.000 description 2
• 235000019197 fats Nutrition 0.000 description 2
• 239000007850 fluorescent dye Substances 0.000 description 2
• 235000013305 food Nutrition 0.000 description 2
• 239000008273 gelatin Substances 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 235000011852 gelatine desserts Nutrition 0.000 description 2
• 238000002523 gelfiltration Methods 0.000 description 2
• 230000009395 genetic defect Effects 0.000 description 2
• 239000001963 growth medium Substances 0.000 description 2
• 210000002216 heart Anatomy 0.000 description 2
• 238000010438 heat treatment Methods 0.000 description 2
• IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
• 108010064060 high density lipoprotein receptors Proteins 0.000 description 2
• 102000054823 high-density lipoprotein particle receptor activity proteins Human genes 0.000 description 2
• 230000006801 homologous recombination Effects 0.000 description 2
• 238000002744 homologous recombination Methods 0.000 description 2
• 230000007062 hydrolysis Effects 0.000 description 2
• 238000006460 hydrolysis reaction Methods 0.000 description 2
• 230000028993 immune response Effects 0.000 description 2
• 230000001771 impaired effect Effects 0.000 description 2
• 239000012535 impurity Substances 0.000 description 2
• 238000010348 incorporation Methods 0.000 description 2
• 208000015181 infectious disease Diseases 0.000 description 2
• 238000007918 intramuscular administration Methods 0.000 description 2
• 150000002500 ions Chemical class 0.000 description 2
• 238000002955 isolation Methods 0.000 description 2
• QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
• 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
• 230000008604 lipoprotein metabolism Effects 0.000 description 2
• 239000006166 lysate Substances 0.000 description 2
• 239000000693 micelle Substances 0.000 description 2
• 238000002156 mixing Methods 0.000 description 2
• 238000010369 molecular cloning Methods 0.000 description 2
• 230000035772 mutation Effects 0.000 description 2
• 201000000050 myeloid neoplasm Diseases 0.000 description 2
• 239000000346 nonvolatile oil Substances 0.000 description 2
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
• 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 2
• 230000002018 overexpression Effects 0.000 description 2
• 230000003647 oxidation Effects 0.000 description 2
• 238000007254 oxidation reaction Methods 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• 230000007170 pathology Effects 0.000 description 2
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
• 102000013415 peroxidase activity proteins Human genes 0.000 description 2
• 108040007629 peroxidase activity proteins Proteins 0.000 description 2
• YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
• 230000035790 physiological processes and functions Effects 0.000 description 2
• 239000006187 pill Substances 0.000 description 2
• 230000003169 placental effect Effects 0.000 description 2
• 210000005059 placental tissue Anatomy 0.000 description 2
• 108700004029 pol Genes Proteins 0.000 description 2
• 230000008488 polyadenylation Effects 0.000 description 2
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
• 230000004481 post-translational protein modification Effects 0.000 description 2
• 210000001236 prokaryotic cell Anatomy 0.000 description 2
• 230000004224 protection Effects 0.000 description 2
• 239000011535 reaction buffer Substances 0.000 description 2
• 239000011541 reaction mixture Substances 0.000 description 2
• 238000007423 screening assay Methods 0.000 description 2
• 230000003248 secreting effect Effects 0.000 description 2
• 230000028327 secretion Effects 0.000 description 2
• 238000010187 selection method Methods 0.000 description 2
• 238000012163 sequencing technique Methods 0.000 description 2
• 239000012679 serum free medium Substances 0.000 description 2
• 239000000741 silica gel Substances 0.000 description 2
• 229910002027 silica gel Inorganic materials 0.000 description 2
• 239000002904 solvent Substances 0.000 description 2
• 238000000527 sonication Methods 0.000 description 2
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
• 238000010254 subcutaneous injection Methods 0.000 description 2
• 239000007929 subcutaneous injection Substances 0.000 description 2
• 125000000446 sulfanediyl group Chemical group *S* 0.000 description 2
• 230000009885 systemic effect Effects 0.000 description 2
• 229960002180 tetracycline Drugs 0.000 description 2
• 229930101283 tetracycline Natural products 0.000 description 2
• 235000019364 tetracycline Nutrition 0.000 description 2
• 150000003522 tetracyclines Chemical class 0.000 description 2
• RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
• GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
• 210000003606 umbilical vein Anatomy 0.000 description 2
• 241001529453 unidentified herpesvirus Species 0.000 description 2
• 230000006439 vascular pathology Effects 0.000 description 2
• 239000002699 waste material Substances 0.000 description 2
• 238000011816 wild-type C57Bl6 mouse Methods 0.000 description 2
• DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
• HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
• CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
• NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
• PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
• WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
• KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical group O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 1
• BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
• FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
• UHBAPGWWRFVTFS-UHFFFAOYSA-N 4,4'-dipyridyl disulfide Chemical compound C=1C=NC=CC=1SSC1=CC=NC=C1 UHBAPGWWRFVTFS-UHFFFAOYSA-N 0.000 description 1
• 101150037123 APOE gene Proteins 0.000 description 1
• 229920000936 Agarose Polymers 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• 101150102415 Apob gene Proteins 0.000 description 1
• PNIGSVZJNVUVJA-BQBZGAKWSA-N Arg-Gly-Asn Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O PNIGSVZJNVUVJA-BQBZGAKWSA-N 0.000 description 1
• 108010002913 Asialoglycoproteins Proteins 0.000 description 1
• YJRORCOAFUZVKA-FXQIFTODSA-N Asn-Arg-Cys Chemical compound C(C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(=O)N)N)CN=C(N)N YJRORCOAFUZVKA-FXQIFTODSA-N 0.000 description 1
• 102100030009 Azurocidin Human genes 0.000 description 1
• 101710154607 Azurocidin Proteins 0.000 description 1
• 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
• 102100026189 Beta-galactosidase Human genes 0.000 description 1
• 101100263837 Bovine ephemeral fever virus (strain BB7721) beta gene Proteins 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 241000701157 Canine mastadenovirus A Species 0.000 description 1
• 241000282465 Canis Species 0.000 description 1
• 101150044789 Cap gene Proteins 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 108090000565 Capsid Proteins Proteins 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• 102100038909 Caveolin-2 Human genes 0.000 description 1
• 102000000844 Cell Surface Receptors Human genes 0.000 description 1
• 108010001857 Cell Surface Receptors Proteins 0.000 description 1
• 101710104316 Cell surface-binding protein Proteins 0.000 description 1
• 102100023321 Ceruloplasmin Human genes 0.000 description 1
• 108010077773 Complement C4a Proteins 0.000 description 1
• 108020004635 Complementary DNA Proteins 0.000 description 1
• 241000557626 Corvus corax Species 0.000 description 1
• 239000004971 Cross linker Substances 0.000 description 1
• 229920000858 Cyclodextrin Polymers 0.000 description 1
• NLCZGISONIGRQP-DCAQKATOSA-N Cys-Arg-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CS)N NLCZGISONIGRQP-DCAQKATOSA-N 0.000 description 1
• CPTUXCUWQIBZIF-ZLUOBGJFSA-N Cys-Asn-Ser Chemical compound SC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O CPTUXCUWQIBZIF-ZLUOBGJFSA-N 0.000 description 1
• 238000000116 DAPI staining Methods 0.000 description 1
• 102000012410 DNA Ligases Human genes 0.000 description 1
• 108010061982 DNA Ligases Proteins 0.000 description 1
• 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
• 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
• 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
• 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
• 101100216294 Danio rerio apoeb gene Proteins 0.000 description 1
• 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
• 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
• 102100036912 Desmin Human genes 0.000 description 1
• 108010044052 Desmin Proteins 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
• 101100290057 Drosophila virilis Mal-B1 gene Proteins 0.000 description 1
• 206010014476 Elevated cholesterol Diseases 0.000 description 1
• 208000005189 Embolism Diseases 0.000 description 1
• 108010042407 Endonucleases Proteins 0.000 description 1
• 102000004533 Endonucleases Human genes 0.000 description 1
• 101100316840 Enterobacteria phage P4 Beta gene Proteins 0.000 description 1
• 108090000371 Esterases Proteins 0.000 description 1
• VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
• 239000005977 Ethylene Substances 0.000 description 1
• 241000206602 Eukaryota Species 0.000 description 1
• 108010054218 Factor VIII Proteins 0.000 description 1
• 102000001690 Factor VIII Human genes 0.000 description 1
• 229920001917 Ficoll Polymers 0.000 description 1
• 108090000331 Firefly luciferases Proteins 0.000 description 1
• 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 1
• 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• LXTRSHQLGYINON-DTWKUNHWSA-N Gly-Met-Pro Chemical compound CSCC[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN LXTRSHQLGYINON-DTWKUNHWSA-N 0.000 description 1
• YJDALMUYJIENAG-QWRGUYRKSA-N Gly-Tyr-Asn Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)CN)O YJDALMUYJIENAG-QWRGUYRKSA-N 0.000 description 1
• JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
• 108091027874 Group I catalytic intron Proteins 0.000 description 1
• 206010019280 Heart failures Diseases 0.000 description 1
• 229920002971 Heparan sulfate Polymers 0.000 description 1
• 208000009889 Herpes Simplex Diseases 0.000 description 1
• 101000889990 Homo sapiens Apolipoprotein(a) Proteins 0.000 description 1
• 101000740981 Homo sapiens Caveolin-2 Proteins 0.000 description 1
• 101001134442 Homo sapiens Pancreatic lipase-related protein 2 Proteins 0.000 description 1
• 101001096022 Homo sapiens Phospholipase B1, membrane-associated Proteins 0.000 description 1
• 240000005979 Hordeum vulgare Species 0.000 description 1
• 235000007340 Hordeum vulgare Nutrition 0.000 description 1
• 102000003839 Human Proteins Human genes 0.000 description 1
• 108090000144 Human Proteins Proteins 0.000 description 1
• 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
• 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
• 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
• 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
• 208000026350 Inborn Genetic disease Diseases 0.000 description 1
• 108090001061 Insulin Proteins 0.000 description 1
• 101710203526 Integrase Proteins 0.000 description 1
• 102000011782 Keratins Human genes 0.000 description 1
• 108010076876 Keratins Proteins 0.000 description 1
• 241000235058 Komagataella pastoris Species 0.000 description 1
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• GPICTNQYKHHHTH-GUBZILKMSA-N Leu-Gln-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O GPICTNQYKHHHTH-GUBZILKMSA-N 0.000 description 1
• WMTOVWLLDGQGCV-GUBZILKMSA-N Leu-Glu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N WMTOVWLLDGQGCV-GUBZILKMSA-N 0.000 description 1
• 108700039553 Lipase-like Proteins 0.000 description 1
• ALSRJRIWBNENFY-DCAQKATOSA-N Lys-Arg-Asn Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O ALSRJRIWBNENFY-DCAQKATOSA-N 0.000 description 1
• DNEJSAIMVANNPA-DCAQKATOSA-N Lys-Asn-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O DNEJSAIMVANNPA-DCAQKATOSA-N 0.000 description 1
• KJIXWRWPOCKYLD-IHRRRGAJSA-N Lys-Lys-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)N KJIXWRWPOCKYLD-IHRRRGAJSA-N 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 102000003792 Metallothionein Human genes 0.000 description 1
• 108090000157 Metallothionein Proteins 0.000 description 1
• 241000713862 Moloney murine sarcoma virus Species 0.000 description 1
• 241000713333 Mouse mammary tumor virus Species 0.000 description 1
• 102000006386 Myelin Proteins Human genes 0.000 description 1
• 108010083674 Myelin Proteins Proteins 0.000 description 1
• 101710107068 Myelin basic protein Proteins 0.000 description 1
• 101710204037 Myosin-2 Proteins 0.000 description 1
• PESQCPHRXOFIPX-UHFFFAOYSA-N N-L-methionyl-L-tyrosine Natural products CSCCC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 PESQCPHRXOFIPX-UHFFFAOYSA-N 0.000 description 1
• 230000004988 N-glycosylation Effects 0.000 description 1
• 241000237955 Nassarius Species 0.000 description 1
• 206010028980 Neoplasm Diseases 0.000 description 1
• 239000004677 Nylon Substances 0.000 description 1
• 240000007817 Olea europaea Species 0.000 description 1
• 108010038807 Oligopeptides Proteins 0.000 description 1
• 102000015636 Oligopeptides Human genes 0.000 description 1
• 239000012570 Opti-MEM I medium Substances 0.000 description 1
• 208000003076 Osteolysis Diseases 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 235000021314 Palmitic acid Nutrition 0.000 description 1
• 108010067372 Pancreatic elastase Proteins 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 229930182555 Penicillin Natural products 0.000 description 1
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
• 108010009711 Phalloidine Proteins 0.000 description 1
• 239000004952 Polyamide Substances 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 208000017855 Progressive familial intrahepatic cholestasis type 1 Diseases 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
• 241001112090 Pseudovirus Species 0.000 description 1
• 108091030071 RNAI Proteins 0.000 description 1
• 239000012979 RPMI medium Substances 0.000 description 1
• 239000012980 RPMI-1640 medium Substances 0.000 description 1
• 206010037888 Rash pustular Diseases 0.000 description 1
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
• 108010052090 Renilla Luciferases Proteins 0.000 description 1
• 241000714474 Rous sarcoma virus Species 0.000 description 1
• 108091005487 SCARB1 Proteins 0.000 description 1
• RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
• 206010039491 Sarcoma Diseases 0.000 description 1
• 102100037118 Scavenger receptor class B member 1 Human genes 0.000 description 1
• 108091081021 Sense strand Proteins 0.000 description 1
• OCWWJBZQXGYQCA-DCAQKATOSA-N Ser-Lys-Met Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(O)=O OCWWJBZQXGYQCA-DCAQKATOSA-N 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• 108010022999 Serine Proteases Proteins 0.000 description 1
• 102000012479 Serine Proteases Human genes 0.000 description 1
• 241000700584 Simplexvirus Species 0.000 description 1
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
• 229920002125 Sokalan® Polymers 0.000 description 1
• 241000713896 Spleen necrosis virus Species 0.000 description 1
• 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
• 206010042434 Sudden death Diseases 0.000 description 1
• 108091008874 T cell receptors Proteins 0.000 description 1
• 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 1
• 239000006180 TBST buffer Substances 0.000 description 1
• 108090000190 Thrombin Proteins 0.000 description 1
• 208000007536 Thrombosis Diseases 0.000 description 1
• 102000004357 Transferases Human genes 0.000 description 1
• 108090000992 Transferases Proteins 0.000 description 1
• 239000013504 Triton X-100 Substances 0.000 description 1
• 229920004890 Triton X-100 Polymers 0.000 description 1
• 102000004243 Tubulin Human genes 0.000 description 1
• 108090000704 Tubulin Proteins 0.000 description 1
• PRONOHBTMLNXCZ-BZSNNMDCSA-N Tyr-Leu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 PRONOHBTMLNXCZ-BZSNNMDCSA-N 0.000 description 1
• 241000700618 Vaccinia virus Species 0.000 description 1
• 206010046865 Vaccinia virus infection Diseases 0.000 description 1
• 206010053648 Vascular occlusion Diseases 0.000 description 1
• 102100035071 Vimentin Human genes 0.000 description 1
• 108010065472 Vimentin Proteins 0.000 description 1
• CESGKXMBHGUQTB-VONOSFMSSA-N [(1S,2S,6R,10S,11R,13S,14R,15R)-1,6,14-trihydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-5-oxo-13-tetracyclo[8.5.0.02,6.011,13]pentadeca-3,8-dienyl] tetradecanoate Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](O)[C@@]3(OC(=O)CCCCCCCCCCCCC)C(C)(C)[C@H]3[C@@H]21 CESGKXMBHGUQTB-VONOSFMSSA-N 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 239000006096 absorbing agent Substances 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 230000001133 acceleration Effects 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 210000004100 adrenal gland Anatomy 0.000 description 1
• 239000000556 agonist Substances 0.000 description 1
• 125000001931 aliphatic group Chemical group 0.000 description 1
• 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
• 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• 125000003368 amide group Chemical group 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 125000000129 anionic group Chemical group 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000000489 anti-atherogenic effect Effects 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 239000000427 antigen Substances 0.000 description 1
• 108091007433 antigens Proteins 0.000 description 1
• 102000036639 antigens Human genes 0.000 description 1
• 239000012062 aqueous buffer Substances 0.000 description 1
• 229940114079 arachidonic acid Drugs 0.000 description 1
• 235000021342 arachidonic acid Nutrition 0.000 description 1
• 210000001367 artery Anatomy 0.000 description 1
• 125000003118 aryl group Chemical group 0.000 description 1
• 229940009098 aspartate Drugs 0.000 description 1
• 238000002820 assay format Methods 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 238000000211 autoradiogram Methods 0.000 description 1
• 210000003050 axon Anatomy 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• FCPVYOBCFFNJFS-LQDWTQKMSA-M benzylpenicillin sodium Chemical compound [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 FCPVYOBCFFNJFS-LQDWTQKMSA-M 0.000 description 1
• 108010005774 beta-Galactosidase Proteins 0.000 description 1
• 210000000941 bile Anatomy 0.000 description 1
• 239000003613 bile acid Substances 0.000 description 1
• 230000000975 bioactive effect Effects 0.000 description 1
• 239000000227 bioadhesive Substances 0.000 description 1
• 230000008827 biological function Effects 0.000 description 1
• 229960002685 biotin Drugs 0.000 description 1
• 235000020958 biotin Nutrition 0.000 description 1
• 239000011616 biotin Substances 0.000 description 1
• 239000003914 blood derivative Substances 0.000 description 1
• 238000009534 blood test Methods 0.000 description 1
• 239000012888 bovine serum Substances 0.000 description 1
• 210000000481 breast Anatomy 0.000 description 1
• 239000007975 buffered saline Substances 0.000 description 1
• 235000019437 butane-1,3-diol Nutrition 0.000 description 1
• 201000011510 cancer Diseases 0.000 description 1
• 229910052799 carbon Inorganic materials 0.000 description 1
• 230000007211 cardiovascular event Effects 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 238000006555 catalytic reaction Methods 0.000 description 1
• 239000003729 cation exchange resin Substances 0.000 description 1
• 229920006317 cationic polymer Polymers 0.000 description 1
• 230000007910 cell fusion Effects 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 210000002230 centromere Anatomy 0.000 description 1
• 125000003636 chemical group Chemical group 0.000 description 1
• 229960001231 choline Drugs 0.000 description 1
• OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• 238000000975 co-precipitation Methods 0.000 description 1
• 238000012761 co-transfection Methods 0.000 description 1
• 230000003081 coactivator Effects 0.000 description 1
• 230000001268 conjugating effect Effects 0.000 description 1
• 239000000470 constituent Substances 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 238000004132 cross linking Methods 0.000 description 1
• 238000011461 current therapy Methods 0.000 description 1
• 238000005520 cutting process Methods 0.000 description 1
• 229940097362 cyclodextrins Drugs 0.000 description 1
• 108010060199 cysteinylproline Proteins 0.000 description 1
• RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
• HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
• NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 238000004925 denaturation Methods 0.000 description 1
• 230000036425 denaturation Effects 0.000 description 1
• 238000000326 densiometry Methods 0.000 description 1
• 239000005547 deoxyribonucleotide Substances 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 210000005045 desmin Anatomy 0.000 description 1
• 229960002086 dextran Drugs 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
• SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
• 238000007865 diluting Methods 0.000 description 1
• BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
• 235000019800 disodium phosphate Nutrition 0.000 description 1
• 208000035475 disorder Diseases 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 239000000975 dye Substances 0.000 description 1
• 239000008157 edible vegetable oil Substances 0.000 description 1
• 230000002900 effect on cell Effects 0.000 description 1
• 230000001278 effect on cholesterol Effects 0.000 description 1
• 238000010828 elution Methods 0.000 description 1
• 230000012202 endocytosis Effects 0.000 description 1
• 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
• 230000037149 energy metabolism Effects 0.000 description 1
• 230000009088 enzymatic function Effects 0.000 description 1
• 238000012869 ethanol precipitation Methods 0.000 description 1
• 230000005284 excitation Effects 0.000 description 1
• 229960000301 factor viii Drugs 0.000 description 1
• 239000012526 feed medium Substances 0.000 description 1
• 239000012894 fetal calf serum Substances 0.000 description 1
• 230000008175 fetal development Effects 0.000 description 1
• 230000001605 fetal effect Effects 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 239000000706 filtrate Substances 0.000 description 1
• 125000001153 fluoro group Chemical group F* 0.000 description 1
• 210000000497 foam cell Anatomy 0.000 description 1
• WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Substances O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
• 238000009472 formulation Methods 0.000 description 1
• 238000005194 fractionation Methods 0.000 description 1
• 238000013467 fragmentation Methods 0.000 description 1
• 238000006062 fragmentation reaction Methods 0.000 description 1
• 230000004927 fusion Effects 0.000 description 1
• 101150098622 gag gene Proteins 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 238000001502 gel electrophoresis Methods 0.000 description 1
• 238000007429 general method Methods 0.000 description 1
• 208000016361 genetic disease Diseases 0.000 description 1
• 210000004907 gland Anatomy 0.000 description 1
• 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
• 229930182470 glycoside Natural products 0.000 description 1
• 150000002338 glycosides Chemical class 0.000 description 1
• 238000003306 harvesting Methods 0.000 description 1
• 210000005003 heart tissue Anatomy 0.000 description 1
• 230000002440 hepatic effect Effects 0.000 description 1
• 230000009716 hepatic expression Effects 0.000 description 1
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
• 125000005842 heteroatom Chemical group 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 102000045903 human LPA Human genes 0.000 description 1
• 229910052739 hydrogen Inorganic materials 0.000 description 1
• 239000001257 hydrogen Substances 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• 208000006575 hypertriglyceridemia Diseases 0.000 description 1
• 210000003016 hypothalamus Anatomy 0.000 description 1
• 210000003090 iliac artery Anatomy 0.000 description 1
• 125000001841 imino group Chemical group [H]N=* 0.000 description 1
• 210000000987 immune system Anatomy 0.000 description 1
• 238000002649 immunization Methods 0.000 description 1
• 238000003119 immunoblot Methods 0.000 description 1
• 229940072221 immunoglobulins Drugs 0.000 description 1
• 238000000099 in vitro assay Methods 0.000 description 1
• 238000005462 in vivo assay Methods 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 230000002458 infectious effect Effects 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 238000013383 initial experiment Methods 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 230000010354 integration Effects 0.000 description 1
• 210000003963 intermediate filament Anatomy 0.000 description 1
• 210000000936 intestine Anatomy 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 238000007914 intraventricular administration Methods 0.000 description 1
• 101150066555 lacZ gene Proteins 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 150000002617 leukotrienes Chemical class 0.000 description 1
• 230000002366 lipolytic effect Effects 0.000 description 1
• 238000004811 liquid chromatography Methods 0.000 description 1
• 210000005228 liver tissue Anatomy 0.000 description 1
• 230000004807 localization Effects 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 238000000464 low-speed centrifugation Methods 0.000 description 1
• 208000029791 lytic metastatic bone lesion Diseases 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• 238000000520 microinjection Methods 0.000 description 1
• 235000013336 milk Nutrition 0.000 description 1
• 239000008267 milk Substances 0.000 description 1
• 210000004080 milk Anatomy 0.000 description 1
• 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
• 235000019799 monosodium phosphate Nutrition 0.000 description 1
• 210000002464 muscle smooth vascular Anatomy 0.000 description 1
• 239000003471 mutagenic agent Substances 0.000 description 1
• 210000005012 myelin Anatomy 0.000 description 1
• 210000000066 myeloid cell Anatomy 0.000 description 1
• 208000010125 myocardial infarction Diseases 0.000 description 1
• 210000004165 myocardium Anatomy 0.000 description 1
• DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical group CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 1
• WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
• 239000002088 nanocapsule Substances 0.000 description 1
• 210000005044 neurofilament Anatomy 0.000 description 1
• 239000002858 neurotransmitter agent Substances 0.000 description 1
• 238000011587 new zealand white rabbit Methods 0.000 description 1
• 231100000065 noncytotoxic Toxicity 0.000 description 1
• 230000002020 noncytotoxic effect Effects 0.000 description 1
• 231100000028 nontoxic concentration Toxicity 0.000 description 1
• 210000004940 nucleus Anatomy 0.000 description 1
• 229920001778 nylon Polymers 0.000 description 1
• 210000004248 oligodendroglia Anatomy 0.000 description 1
• 238000005457 optimization Methods 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 230000008520 organization Effects 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• 229910052760 oxygen Inorganic materials 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
• 108010059531 pancreatic lipase-related protein 1 Proteins 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 229940049954 penicillin Drugs 0.000 description 1
• 239000008194 pharmaceutical composition Substances 0.000 description 1
• 239000002644 phorbol ester Substances 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
• 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
• 150000004713 phosphodiesters Chemical class 0.000 description 1
• 150000008300 phosphoramidites Chemical class 0.000 description 1
• 229950004354 phosphorylcholine Drugs 0.000 description 1
• 229920001992 poloxamer 407 Polymers 0.000 description 1
• 229940044476 poloxamer 407 Drugs 0.000 description 1
• 229920002647 polyamide Polymers 0.000 description 1
• 208000030683 polygenic disease Diseases 0.000 description 1
• 238000003752 polymerase chain reaction Methods 0.000 description 1
• 108091033319 polynucleotide Proteins 0.000 description 1
• 102000040430 polynucleotide Human genes 0.000 description 1
• 239000002157 polynucleotide Substances 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 239000013641 positive control Substances 0.000 description 1
• 238000011533 pre-incubation Methods 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000009862 primary prevention Effects 0.000 description 1
• 150000003180 prostaglandins Chemical class 0.000 description 1
• 239000003531 protein hydrolysate Substances 0.000 description 1
• 230000002797 proteolythic effect Effects 0.000 description 1
• 230000006337 proteolytic cleavage Effects 0.000 description 1
• 230000002685 pulmonary effect Effects 0.000 description 1
• 150000003230 pyrimidines Chemical class 0.000 description 1
• 238000011552 rat model Methods 0.000 description 1
• 238000003753 real-time PCR Methods 0.000 description 1
• 238000003259 recombinant expression Methods 0.000 description 1
• 230000006798 recombination Effects 0.000 description 1
• 238000005215 recombination Methods 0.000 description 1
• 238000004064 recycling Methods 0.000 description 1
• 210000005084 renal tissue Anatomy 0.000 description 1
• 101150066583 rep gene Proteins 0.000 description 1
• 230000003362 replicative effect Effects 0.000 description 1
• 230000004044 response Effects 0.000 description 1
• 108091008146 restriction endonucleases Proteins 0.000 description 1
• 108090000064 retinoic acid receptors Proteins 0.000 description 1
• 102000003702 retinoic acid receptors Human genes 0.000 description 1
• 238000010839 reverse transcription Methods 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 239000003161 ribonuclease inhibitor Substances 0.000 description 1
• 150000003839 salts Chemical class 0.000 description 1
• 238000002821 scintillation proximity assay Methods 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 238000012216 screening Methods 0.000 description 1
• 230000009863 secondary prevention Effects 0.000 description 1
• 238000003375 selectivity assay Methods 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 238000002864 sequence alignment Methods 0.000 description 1
• 239000003001 serine protease inhibitor Substances 0.000 description 1
• 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
• 230000035939 shock Effects 0.000 description 1
• RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
• 229960002855 simvastatin Drugs 0.000 description 1
• 239000002002 slurry Substances 0.000 description 1
• 210000002460 smooth muscle Anatomy 0.000 description 1
• 230000029547 smooth muscle hypertrophy Effects 0.000 description 1
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• 229910000162 sodium phosphate Inorganic materials 0.000 description 1
• 235000011008 sodium phosphates Nutrition 0.000 description 1
• 230000009870 specific binding Effects 0.000 description 1
• 238000004611 spectroscopical analysis Methods 0.000 description 1
• 230000006641 stabilisation Effects 0.000 description 1
• 238000011105 stabilization Methods 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 230000002966 stenotic effect Effects 0.000 description 1
• 239000008223 sterile water Substances 0.000 description 1
• 239000003270 steroid hormone Substances 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 229960005322 streptomycin Drugs 0.000 description 1
• 229960002385 streptomycin sulfate Drugs 0.000 description 1
• 125000001424 substituent group Chemical group 0.000 description 1
• 125000004434 sulfur atom Chemical group 0.000 description 1
• 125000004354 sulfur functional group Chemical group 0.000 description 1
• 238000011477 surgical intervention Methods 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• XQTLDIFVVHJORV-UHFFFAOYSA-N tecnazene Chemical compound [O-][N+](=O)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl XQTLDIFVVHJORV-UHFFFAOYSA-N 0.000 description 1
• 230000002381 testicular Effects 0.000 description 1
• 210000001550 testis Anatomy 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• 230000008719 thickening Effects 0.000 description 1
• 229960004072 thrombin Drugs 0.000 description 1
• 231100000027 toxicology Toxicity 0.000 description 1
• 230000005030 transcription termination Effects 0.000 description 1
• 238000010361 transduction Methods 0.000 description 1
• 230000026683 transduction Effects 0.000 description 1
• 238000003146 transient transfection Methods 0.000 description 1
• 150000003852 triazoles Chemical class 0.000 description 1
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
• 241001515965 unidentified phage Species 0.000 description 1
• 208000007089 vaccinia Diseases 0.000 description 1
• 208000021331 vascular occlusion disease Diseases 0.000 description 1
• 210000003462 vein Anatomy 0.000 description 1
• 210000005048 vimentin Anatomy 0.000 description 1
• 230000029812 viral genome replication Effects 0.000 description 1
• 210000002845 virion Anatomy 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• NLIVDORGVGAOOJ-MAHBNPEESA-M xylene cyanol Chemical compound [Na+].C1=C(C)C(NCC)=CC=C1C(\C=1C(=CC(OS([O-])=O)=CC=1)OS([O-])=O)=C\1C=C(C)\C(=[NH+]/CC)\C=C/1 NLIVDORGVGAOOJ-MAHBNPEESA-M 0.000 description 1
• 210000005253 yeast cell Anatomy 0.000 description 1
• DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1